![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 18, 15697-15702, May 3, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Molecular Cell Biology, Weizmann Institute
of Science, Rehovot 76100, Israel and
Received for publication, December 18, 2001, and in revised form, February 13, 2002
Nitric oxide (NO) is an important bioactive
molecule involved in a variety of physiological and pathological
processes. At the same time, NO is also an inducer of stress signaling,
owing to its ability to damage proteins and DNA. NO was reported to be
a potent activator of the p53 tumor suppressor protein. However, the
mechanisms underlying p53 activation by NO remain to be elucidated. We
report here that NO induces the accumulation of transcriptionally active p53 in a variety of cell types and that NO signaling to p53 does
not require ataxia telangiectasia-mutated (ATM), poly(ADP-ribose) polymerase 1, or the ARF tumor suppressor protein. In mouse embryonic fibroblasts, NO elicits a down-regulation of Mdm2 protein levels that
precedes the rise in p53. NO-induced down-regulation of Mdm2 protein
but not its mRNA also occurs in several p53-deficient cell types
and is thus p53-independent. The drop in endogenous Mdm2 levels
following NO treatment is accompanied by a corresponding reduction in
the rate of p53 ubiquitination. Thus, the down-regulation of Mdm2 by NO
is likely to contribute to the activation of p53.
p53 is one of the best studied tumor suppressors. It is now
appreciated that p53 is a pivotal integrator of stress signaling, and
that many diverse types of stress can evoke a p53 response (1, 2). p53
is typically a very short-lived protein under normal conditions because
of its fast proteasomal degradation. A key feature of the p53 response
is p53 stabilization, leading to a rapid increase in p53 steady-state
levels. Abundant evidence indicates that p53 stabilization largely
relies on post-translational events that uncouple p53 from its
proteasomal degradation (3, 4). A major
E31 ubiquitin ligase for p53,
whose activity serves as a rate-limiting factor for p53 degradation, is
Mdm2 (5-7). Interestingly, the expression of the mdm2 gene
is regulated by p53 itself (8, 9). This p53-Mdm2 autoregulatory
feedback loop has been a focus of research in recent years, leading to
the realization that many stress signals impinge on this loop to
modulate the physical and functional interplay between p53 and Mdm2.
Different types of stress engage different mechanisms to uncouple the
p53-Mdm2 feedback loop (10). In the case of ionizing radiation,
the ATM kinase is essential for the rapid accumulation of p53. Ionizing
radiation gives rise to at least three ATM-dependent events
that impact on the p53-Mdm2 feedback loop, i.e. the
phosphorylation of p53 on Ser-15 and Mdm2 on Ser-395 by ATM itself
(11-13), and on Ser-20 of p53 by ATM-activated CHK2, a human
checkpoint kinase (14, 15). In the case of aberrant oncogene
expression, oncogenes such as c-Myc, Ras, and Nitric oxide (NO) is an important bioactive molecule involved in a
variety of physiological and pathological processes. This membrane
permeable and extremely short-lived (biological half-life: 1-10 s)
molecule has been shown to be a regulator of cell killing by
macrophages, a mediator of vasodilation and a neurotransmitter. Virtually every type of mammalian cell is under the influence of NO
(22), because it is widely and actively synthesized. NO can be formed
either by specific nitric-oxide synthases, which metabolize arginine to
citrulline with the formation of NO or by nonenzymatic mechanisms
involving the reduction of nitrite to NO under acidic and highly
reduced conditions (reviewed in Ref. 23). NO can be stored in the form
of S-nitrosothiols. In fact, S-nitrosothiols
formed upon the reaction of NO with redox-activated thiols represent an
active storage pool for NO (reviewed in Ref. 24).
The ability of NO to induce p53 accumulation has been observed in
several studies. p53 accumulation was shown to occur upon treatment
with exogenous NO donors in primary normal human fibroblasts, the
murine monocyte/macrophage cell line RAW 264.7, the human promyelocytic
leukemia cell line U937, and the human glioblastoma cell line A172
(25-27). However, the molecular mechanisms underlying the induction of
p53 by NO have not been elucidated. We now report that NO signaling to
p53 is independent of ATM, poly(ADP-ribose) polymerase 1 (PARP-1), or
ARF. Of note, the induction of p53 by NO is preceded by a decrease in
Mdm2 protein levels. This down-regulation of Mdm2 may be one of the
events that contribute to p53 activation by NO.
Cells and Tissue Culture--
Primary mouse embryonic
fibroblasts (MEFs) were prepared from day 13.5 embryos and propagated
at 37 °C in Dulbecco's modified Eagle's medium supplemented with
nonessential amino acids, 60 µM Chemicals--
s-Nitroso-n-acetylpenicillamine
(SNAP) (Sigma) and S-nitroso-glutathione (GSNO) (Alexis
Biochemicals) were dissolved in PBS Retroviral Infection--
High titer retroviral stocks were
produced by transfecting retroviral constructs pBabe-puro or pBabe-PARP
into 293T cells (2 × 106/10-cm dish) by the calcium
phosphate coprecipitation method together with the ecotropic packaging
vector pSV- Transfections--
HCT116 cells were plated at 0.5 × 106/6-cm plate and transfected with the aid of the JetPEI
reagent (PolyPlus Transfection) according to the manufacturer's
instructions. Transfection efficiencies were typically above 70%. GSNO
treatment was performed 18 h after transfection.
RNA Analysis--
Total RNA was extracted using the
ULTRASPEC (Biotex Laboratories) reagent. Semi-quantitative reverse
transcriptase (RT)-PCR was performed as described previously (29) using
the following primer combinations: hp53, 5'-TGCAGCTGTGGGTTGATTC-3' and
5'-TCCGTCCCAGTAGATTACCA-3'; hp21, 5'-CGCGACTGTGATGCGCTAATG-3' and
5'-GGAACCTCTCATTCAACCGCC-3'; HDM2, 5'-GTGCAATACCAACATGTCTG-3' and
5'-GCATCAAGATCCGGATTCGA-3'; Mdm2, 5'-CGACTATTCCCAACCATCG-3' and
5'-CTAGTTGAAGTAACTTAGCACAAT-3'; and GAPDH, 5'-CAGCAATGCATCCTGCACC-3'
and 5'-TGGACTGTGGTCATGAGCCC-3'.
Immunoblotting Analysis--
Cells were washed with ice-cold PBS
and lysed in radioimmune precipitation buffer. After three rounds of
vigorous vortexing at 5-min intervals, the lysates were cleared by
centrifugation at 4 °C for 10 min. Aliquots containing 20 µg of
total protein (Bio-Rad protein assay) were resolved on 10%
SDS-polyacrylamide gels and transferred to nitrocellulose membranes
(BA83, Schleicher & Schuell). Membranes were probed with the antibodies
indicated in the corresponding figure legends and developed with the
ECL kit (Amersham Biosciences).
NO Induces p53 Accumulation in a Variety of Cell Types--
To
test the generality of the p53 response to NO, several different cell
types were exposed to NO donors (either SNAP or GSNO), and p53 protein
levels were monitored by Western blot analysis. A significant induction
of endogenous p53 was seen in all wild type p53-containing cell types
tested including the U2-OS human osteosarcoma cell line (Fig.
1A), the ML-1 human myeloid
leukemia cell line (Fig. 1B), WI-38 human diploid
fibroblasts (Fig. 1C), and MEFs (Fig. 3). The accumulation
of p53 was time-dependent (Fig. 1A) and NO donor
concentration-dependent (Fig. 1B) and was seen
with both SNAP (Fig. 1, A and B) and GSNO (Fig.
1C). Importantly, the addition of a NO scavenger, C-PTIO (10 µM), completely abolished the GSNO-induced increase in
p53 but not the induction of p53 by ionizing radiation (Fig.
1C, lower panel), confirming that the effect of
GSNO on p53 is indeed mediated specifically by NO. Hence, in agreement
with earlier reports (25-27, 30), the pathways linking NO signaling to
p53 are functional in many cell types including cancer-derived cells
that retain wild type p53 expression.
The accumulation of p53 in response to NO was accompanied by induction
of the p53 target genes p21/Waf1 (Fig.
2A) and hdm2 (Fig.
2B) observed at both protein and mRNA levels. Hence, as reported previously (31), the p53 protein induced by NO is
transcriptionally active.
NO Increases p53 Protein Stability--
The increase in p53
protein in response to NO might be because of either increased levels
of p53 mRNA or translational and post-translational events.
However, no changes in the concentration of p53 mRNA could be found
when p53-specific RT-PCR analysis was performed with the samples used
in Fig. 2 (data not shown). Hence, we asked whether the accumulation of
p53 was attributed to increased protein stability. To that end, a
cycloheximide chase experiment was performed with MEFs maintained
either in the presence or absence of the NO donor GSNO. As shown in
Fig. 3, exposure to GSNO elicited a
significant prolongation of the half-life of p53. An analysis by
quantitative densitometry revealed that whereas the half-life of p53 in
untreated MEFs was ~15 min, it increased to 140 min in GSNO-treated
cells (data not shown). Thus, NO can indeed reduce the rate of p53
degradation and cause p53 protein stabilization; this is in line with
the observations of Ho et al. (30) using cancer cell
lines.
Induction of p53 by NO Is Independent of ATM, PARP, and
ARF--
NO can modify proteins by nitrosylation or nitration as well
as cause DNA strand breaks (32, 33). The ATM kinase plays a pivotal
role in the induction of p53 by agents such as ionizing radiation,
which cause double strand DNA breaks (34, 35). Therefore, it is
conceivable that NO may lead to p53 accumulation through induction of
double strand breaks and consequent activation of ATM. This notion was
addressed by comparing the ability of NO to cause p53 accumulation in
cells with different ATM status. As shown in Fig.
4A, NO induced p53 to
comparable levels in fibroblasts retaining a functional allele of the
ATM gene (ATM +/
An attractive candidate for mediating the activation of p53 by NO is
the enzyme PARP-1. NO is a potent activator of PARP-1 through its
ability to cause single strand DNA breaks (37, 38). Furthermore, PARP-1
can engage in direct protein-protein interactions with p53 (39).
Therefore, we compared the induction of p53 by NO in 3T3 fibroblasts
from PARP-1 knock-out mice (40) and in derivatives of these 3T3
fibroblasts in which PARP-1 expression had been reconstituted by
infection with a PARP-1 retrovirus. As shown in Fig. 4B,
there was no measurable difference between these two cell types with
regard to either p53 protein accumulation or induction of Mdm2, a
product of a p53 target gene. Thus, PARP-1 appears dispensable for the
activation of p53 by NO.
Some signaling pathways, in particular oncogenic stress, lead to p53
stabilization by triggering the synthesis of the ARF tumor suppressor
protein (17). The binding of ARF to Mdm2 inactivates the latter and
renders p53 more stable. Therefore, it was of interest to find out
whether ARF played a role in the signaling from NO to p53. To that end,
the effect of NO on p53 was studied in MEFs from ARF-null mice and in
their wild type counterparts. As seen in Fig. 4C, the
ablation of ARF expression did not compromise the ability of NO to
promote an increase in the steady-state levels of p53 and Mdm2,
implying that ARF is not required for the activation of p53 by NO.
NO Down-regulates Mdm2 Protein Levels--
Because the degradation
of p53 is largely dependent on the activity of Mdm2, we performed a
more detailed time course analysis of p53 and Mdm2 in wild type MEFs
exposed to NO donors. Unexpectedly, although extended exposure to NO
augmented the levels of Mdm2 owing to the activation of the
mdm2 gene by p53 (see Fig. 4C), an opposite
picture was revealed at early phases of the NO response. As seen in
Fig. 5A, exposure of MEFs to
GSNO led to a rapid drop in Mdm2 protein, clearly preceding the rise in
p53. As expected, Mdm2 levels increased again and became further
augmented at later time points, subsequent to the induction of p53 as
also seen in Fig. 2B.
The ability of NO to modulate the levels of Mdm2 was further explored
in p53-null cells where the analysis is made simpler by the absence of
a later Mdm2 induction attributed to p53 activation. Indeed, incubation
of p53-deficient H1299 human lung adenocarcinoma cells with GSNO
resulted in a substantial and extended drop in Hdm2 (Fig.
5B). Consistent with the absence of p53, a second wave of
Hdm2 induction did not occur in these cells. A pronounced decrease in
Mdm2 quantified with the aid of two different monoclonal antibodies was
also evident in GSNO-treated p53-null MEFs (Fig. 5C,
left-hand panel). This decrease was not the result of
down-modulation of mdm2 mRNA, because semi-quantitative
RT-PCR analysis did not reveal any significant change in the
concentration of the corresponding transcripts (Fig. 5C,
right-hand panel). Together, these observations support the
notion that the induction of p53 by NO, at least in the early phase of
the response, is achieved through down-regulation of Mdm2 protein levels.
NO Attenuates p53 Ubiquitination by Endogenous Mdm2--
Mdm2
promotes p53 degradation by driving p53 ubiquitination. Therefore, it
appeared plausible that the stabilization of p53 by NO is attributed to
reduced p53 ubiquitination as a result of the drop in total Mdm2
levels. This observation was investigated in p53-deficient human
colorectal carcinoma HCT116 cells (28). First, to confirm that the
effect of NO could also be exerted on exogenous p53, these cells were
transfected with a very small amount of p53 expression plasmid. As seen
in Fig. 6A, NO indeed augmented the accumulation of the transfected p53 protein along with a
reduction in the levels of endogenous Hdm2 protein. However, the total
amounts of p53 produced in these transfected cultures were too low to
allow further analysis of p53 ubiquitination. Therefore, a similar
experiment was performed using higher inputs of p53 expression plasmid
DNA. An analysis of relatively small aliquots of the resultant cell
extracts revealed again the expected drop in Hdm2 (Fig. 6B,
right-hand panel). However, this time there was no
significant increase in p53, presumably because the transfected p53 was
in large excess over endogenous Hdm2. These conditions simplified the
quantitative analysis of p53 ubiquitination, because no adjustment had
to be made for differences in total p53 protein. Importantly, when
larger amounts of the same extracts were subjected to analysis with
p53-specific antibodies, a significant reduction was observed in the
intensity of the bands corresponding to ubiquitinated forms of p53
(Fig. 6B, left-hand panel). A similar picture was seen when HCT116 cells were cotransfected with expression plasmids for
p53 and hemagglutinin-ubiquitin followed by analysis of p53-ubiquitin conjugates (data not shown). Hence, the NO-induced drop in total Mdm2
protein is accompanied by a corresponding drop in p53 ubiquitination, which presumably underlies the subsequent stabilization of p53.
The mechanisms underlying the stress-induced stabilization and
activation of p53 are being extensively studied (3, 4, 10, 41, 42).
Although the ability of NO to up-regulate p53 is well documented, the
detailed molecular analysis of the underlying mechanisms is complicated
by the fact that NO is a very pleiotropic agent, which can cause
several different types of protein modifications, lipid oxidation, and
DNA strand breaks. NO causes DNA damage through its derivatives
dinitrogen trioxide (N2O3 = NO + NO2 Rather, our data suggest that a biphasic mechanism is responsible for
the up-regulation of p53 by NO. In the first phase, typically occurring
within a few hours after exposure, NO leads to a pronounced decrease in
Mdm2 protein levels. This is followed by a drop in p53 ubiquitination,
leading to an initial rise in p53 protein. It is conceivable that the
lower levels of Mdm2 also enable p53 to escape more efficiently the
inhibitory effects because of the masking of its transactivation domain
by the bound Mdm2. As a consequence, the accumulated p53 is likely to
be more active as a transcription factor. In the second phase, Mdm2
levels rise again as a result of the transactivation of the
mdm2 gene by the activated p53. This phase presumably occurs
only if the high levels of NO persist beyond the first few hours. At
present, our findings do not explain the ability of p53 to persist at
elevated levels despite this surge in Mdm2 expression. However, as is
the case in other stress conditions, it is conceivable that this
persistence is at least in part the result of multiple covalent
modifications on both p53 and Mdm2 (3, 4, 10, 41, 42). Of note, it has
been reported that NO elicits a specific pattern of p53 phosphorylation
events that is distinct from that known to occur in response to other
stress signals (31). Such phosphorylation might underlie, at least to
some extent, the resistance of p53 to Mdm2 after long exposure to
NO.
Down-regulation of Mdm2 has been observed in a number of other
situations that give rise to p53 activation including UV radiation and
several DNA-damaging cancer therapy agents, as well as hypoxia (10,
50-52). With UV and other DNA-damaging agents, the ablation of Mdm2
was found to be largely the result of down-regulation of
mdm2 gene expression. As shown here, this is not the case
for NO, because no change in the abundance of mdm2
transcripts could be observed at a time when Mdm2 protein levels were
markedly reduced. In contrast, the mechanism underlying the
down-modulation of Mdm2 by hypoxia (52) could be more similar to that
employed by NO, particularly because hypoxia can up-regulate cellular
NO levels through induction of iNOS expression (53, 54). In that
regard, it is of note that p53 has been shown to be a negative
regulator of iNOS expression (26). Thus, iNOS appears to be part of a negative autoregulatory feedback loop, which on one hand the NO generated by iNOS drives p53 activation, whereas on the other hand this
activated p53 down-regulates iNOS expression and thereby restrains
further NO production (26).
In conclusion, our findings further underscore the multiplicity of
molecular mechanisms employed by different stress signals to activate
p53 as well as the central role of Mdm2 in these signaling pathways.
We thank Drs. J. F. Martinez Leal
and H. Matsumoto for helpful advice, Dr. C. Sherr for ARF knock-out
cells, Dr. B. Vogelstein for p53-deleted HCT116 cells, and Dr. G. Lozano for 35-8 cells.
*
This work was supported in part by NCI, National Institutes
of Health Grant RO1 CA 40099, The U. S. A.-Israel Binational Science Foundation, the Kadoorie Charitable Foundations, the Center for Excellence Program of the Israel Science Foundation, and the Yad Abraham Center for Cancer Diagnosis and Therapy.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Tel.: 972-8-9342358;
Fax: 972-8-9465223; E-mail: moshe.oren@weizmann.ac.il.
Published, JBC Papers in Press, February 26, 2002, DOI 10.1074/jbc.M112068200
The abbreviations used are:
E3, ubiquitin-protein isopeptide ligase;
ATM, ataxia
telangiectasia-mutated;
ARF, Alternative Reading Frame product of the
INK4A tumor suppressor locus;
NO, nitric oxide;
iNOS, inducible
nitric-oxide synthase;
MEF, mouse embryonic fibroblasts;
FBS, fetal
bovine serum;
PARP-1, poly(ADP-ribose) polymerase 1;
SNAP, s-nitroso-n-acetylpenicillamine;
GSNO, S-nitroso-glutathione;
PBS, phosphate-buffered saline;
C-PTIO, 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide;
RT, reverse transcriptase.
p53 Activation by Nitric Oxide Involves Down-regulation of
Mdm2*
, and
Unite 9003 du
CNRS, Ecole Superieure de Biotechnologie de Strasbourg,
67400 Illkirch-Graffenstaden, France
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-catenin induce the
expression of ARF, which binds to Mdm2 and inhibits its E3
ubiquitin ligase activity (16-19). Moreover, the binding of ARF to
Mdm2 can sequester Mdm2 in the nucleolus (20, 21). Both of these
mechanisms are proposed to reduce p53 ubiquitination and thereby
increase its stability.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-mercaptoethanol, and
10% heat-inactivated fetal bovine serum (FBS, Sigma). MEFs were
typically used after four passages in culture. AG03057 (ATM +/
,
wtp53, mother) and AG03058 (ATM
/
, wtp53, daughter) cells were
obtained from the National Institute of General Medical Sciences Human
Genetic Mutant Cell Repository (Coriell Institute, Camden, NJ). AG03057
and AG03058 and WI-38 cells (human fetal lung fibroblasts, wtp53) were
maintained in minimum Eagle's medium supplemented with 20%
non-heat-inactivated FBS. ARF knock-out MEFs were obtained from Dr. C. Sherr. p53-null mouse fibroblasts (line 35-8) were from Dr. G. Lozano.
C3 cells (ATM +/
human lymphocytes immortalized by Epstein-Barr
Virus) were obtained from Dr. Y. Shiloh. PARP knock-out 3T3 cells and ARF-null and p53-null mouse fibroblasts as well as U2-OS cells (human
osteosarcoma, wtp53) were maintained at 37 °C in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated FBS.
ML-1 (human leukemic cells, wtp53), H1299 cells (human lung adenocarcinoma, p53-null), and C3 cells were maintained at 37 °C in
RPMI 1640 medium supplemented with 10% heat-inactivated FBS. HCT116
colorectal carcinoma cells in which the p53 gene has been eliminated by
somatic knock-out (28) were provided by Dr. B. Vogelstein and
maintained in McCoy's 5A medium supplemented with 10% FBS.
/
at a concentration of 50 mM and stored at
80 °C in small aliquots. C-PTIO
(Biomol Research Laboratories, Inc.) was dissolved in PBS
/
at 10 mM, stored at
80 °C, and used at a final concentration of 10 µM. MG132 (Calbiochem) was dissolved in
Me2SO at a concentration of 50 mM and
used at a final concentration of 25 µM. Cycloheximide (Sigma) was dissolved in PBS
/
at 10 mg/ml and used at a final concentration of 10 µg/ml.
E-MLV, providing ecotropic packaging helper function.
Virus-containing culture supernatants were collected 24-72 h
post-transfection at 6-h intervals and pooled together. PARP knock-out
3T3 cells (2 × 105/10-cm dish) were infected with
filtered supernatants. Fresh supernatants were added three times at 4-h
intervals. 48 h post-infection, cells were trypsinized and
replated for experiments.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (31K):
[in a new window]
Fig. 1.
Time and dose-dependent induction
of p53 by NO in different cell types. A, U2-OS human
osteosarcoma cells were exposed to the NO donor SNAP at a final
concentration of 0.5 mM. Cell extracts were prepared after
different times of treatment as indicated in hours
(T(h)) above each lane. Aliquots containing equal
amounts of total protein were subjected to Western blot analysis with a
mixture of the p53-specific antibodies DO-1 and PAb1801. B,
ML-1 human myeloid leukemia cells were exposed to the indicated amounts
of SNAP. Extracts were prepared after 10 h of treatment and
processed as in A but using the p53-specific antibody
PAb421. C, WI-38 human diploid fibroblasts were exposed to 8 Grays of ionizing radiation (IR) from a
-ray source or to
the NO donor GSNO (1 mM final concentration). In the
cultures analyzed in the bottom panel, the NO scavenger
c-PTIO was added to the medium 1 h before treatment. Extracts were
prepared and analyzed as in A. Ctr, nontreated
control.

View larger version (33K):
[in a new window]
Fig. 2.
NO-induced p53 is transcriptionally
active. C3 human lymphocytes were treated with 1 mM
GSNO. A, protein extracts and total RNA were prepared at
various time points after the addition of GSNO. B, both
protein and RNA were extracted from parallel cultures after 4 h of
treatment. Changes in protein and mRNA levels of the p53 target
genes p21 (A) and hdm2 (B)
were monitored by Western blot analysis and semi-quantitative RT-PCR,
respectively. p53 protein was assessed as in Fig. 1. Ctr,
nontreated control. IR, ionizing radiation
-irradiation
(8 Grays). GAPDH mRNA was used as a control reference for total
mRNA levels.

View larger version (28K):
[in a new window]
Fig. 3.
NO induces p53 protein stabilization.
Primary MEFs were incubated for 6 h in the presence or absence of
1 mM GSNO. At that point, cycloheximide (CHX)
was added to all cultures to a final concentration of 10 µg/ml.
Extracts were prepared at the indicated time points thereafter and
subjected to Western blot analysis with a mixture of the p53-specific
monoclonal antibodies PAb421 and PAb248. Vinculin was used as a loading
control.
) and in their counterparts lacking
completely ATM function (ATM
/
). As expected and unlike the case for
NO, the induction of p53 by ionizing radiation was severely impaired in
these ATM-null cells (data not shown). It is of note that basal p53
levels were moderately constitutively elevated in the ATM-null cells
(Fig. 4A). Hence, ATM activity is dispensable for the
activation of p53 by NO. This conclusion was also confirmed by
monitoring the reactivity of Mdm2 with the monoclonal antibody 2A10.
Phosphorylation of Mdm2 by ATM leads to a substantial drop in 2A10
reactivity (13, 36). However, exposure of cells to NO did not cause any
measurable change in the reactivity of Mdm2 with 2A10 (data not shown),
arguing that NO does not trigger ATM activation.

View larger version (26K):
[in a new window]
Fig. 4.
Induction of p53 by NO occurs independently
of ATM, PARP-1, or ARF. A, human diploid fibroblasts
heterozygous or homozygous for ATM gene mutations
(ATM +/
and ATM
/
, respectively) were
treated with the NO donor GSNO (1 mM) for 10 h.
Steady-state levels of p53 were determined by Western blot analysis
using a mixture of PAb1801 and DO-1. The same membrane was subsequently
probed for vinculin as a loading control. B, PARP-1
knock-out mouse 3T3 fibroblasts were infected either with a recombinant
retrovirus encoding PARP-1 (v-PARP-1,+) or with control
pBabe-puro retrovirus (v-PARP-1,
) and
incubated with or without 1 mM GSNO for 10 h. Cell
extracts were subjected to Western blot analysis using a mixture of the
p53-specific monoclonal antibodies PAb421 and PAb248, the Mdm2-specific
monoclonal antibody 2A10, or a polyclonal antibody directed against
PARP-1.
-Tubulin served as a loading control. C,
embryonic fibroblasts derived either from control mice
(MEFs) or from ARF-knock-out mice (ARF
/
) were
treated with 1 mM GSNO for 10 h. p53, Mdm2, and
-tubulin were analyzed as in B. The upper band
in the apparent p53 doublet is probably a nonspecific background
band.

View larger version (31K):
[in a new window]
Fig. 5.
Down-regulation of Mdm2 by NO.
A, wild type MEFs were treated with 1 mM GSNO
for the indicated times. Cell extracts were prepared and subjected to
Western blot analysis of p53, Mdm2, and
-tubulin as a loading
control. Antibodies were as in Fig. 4B. The upper
band in the apparent p53 doublet is probably a nonspecific
background band. B, H1299 cells were treated with 1 mM GSNO for 4 or 10 h, and Hdm2 was detected with
monoclonal antibody 2A9.
-Catenin was used as a loading control.
C, spontaneously immortalized fibroblasts derived from p53
knock-out mice (cell line 35-8) were treated with 1 mM GSNO
for 1, 2, or 4 h. At each time point, protein extracts and total
RNA were prepared from parallel cultures. Protein extracts were
subjected to Western blot analysis using separately the Mdm2-specific
monoclonal antibodies 2A10 and 4B2. RNA samples were subjected to
semi-quantitative RT-PCR using primers specific for either Mdm2 or
GAPDH as a control.

View larger version (24K):
[in a new window]
Fig. 6.
NO attenuates p53 ubiquitination.
A, HCT116 human colorectal carcinoma cells, rendered
p53-null by somatic gene knock-out, (28) were transfected with 2 ng of
p53 expression plasmid/6-cm dish, employing the JetPEI reagent. 18 h later, cells were treated with 1 mM GSNO for 2 h.
Protein extracts were prepared and subjected to Western blot analysis
of Hdm2 (monoclonal antibody 2A9) and p53 (mixture of monoclonal
antibodies PAb1801 and DO-1). A green fluorescent protein expression
plasmid was also included in all transfections as a control, and the
corresponding protein was visualized with the aid of a green
fluorescent protein-specific antibody (Roche Molecular Biochemicals).
B, p53-null HCT116 cells were transfected with 50 ng of p53
expression plasmid/6-cm dish, employing the JetPEI reagent. 18 h
later, cells were treated with 1 mM GSNO for 10 h, and
cell extracts were subjected to Western blot analysis using the same
antibodies as in A. The right-hand side panels of
B depict the analysis of a small amount of extract;
endogenous vinculin served as a loading control. In the left-hand
side panel of B, larger amounts of the same extracts
were loaded to enable better visualization of ubiquitinated forms of
p53 (Ub-p53).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
) and
peroxynitrite (ONOO
). The resultant types of DNA damage
include cross-linking, formation of abasic sites, and single strand
breaks (reviewed in Ref. 32). The utilization of cells bearing
deficiencies in several DNA damage-induced pathways enabled us to rule
out some of those pathways as key mediators of the activation of p53 by
NO. Thus, ATM was found to be dispensable for such activation, arguing
against a major role of double-stranded DNA breaks. A more probable
candidate was PARP-1, because this enzyme can be strongly activated by
NO and because it has been implicated by several studies in the DNA damage-induced p53 response (43-46). Furthermore, PARP-1
coimmunoprecipitates with p53 and can bind noncovalently to three
different regions of p53 (residues 153-178, 231-253, and 326-348),
one of which is adjacent to the p53 nuclear export signal (39, 47, 48). The binding of PARP-1 to the p53 region adjacent to its nuclear export
signal raises the interesting possibility that PARP-1 might increase the nuclear retention of p53 and thereby stabilize it. However, our findings do not support a role for PARP-1 in NO signaling to p53. Nevertheless, we can not rule out the possibility that the
recently described PARP-2 protein (49) as well as other DNA
damage-induced signaling events may play a role in p53 activation by
NO. Similarly, our findings also appear to exclude ARF as a major
contributor to NO-induced p53 accumulation. This sets NO clearly apart
from oncogenic stress, which utilizes ARF to neutralize Mdm2-mediated
p53 ubiquitination and degradation (17).
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Vogelstein, B.,
Lane, D.,
and Levine, A. J.
(2000)
Nature
408,
307-310[CrossRef][Medline]
[Order article via Infotrieve] 2.
Evan, G. I.,
and Vousden, K. H.
(2001)
Nature
411,
342-348[CrossRef][Medline]
[Order article via Infotrieve] 3.
Oren, M.
(1999)
J. Biol. Chem.
274,
36031-36034 4.
Woods, D. B.,
and Vousden, K. H.
(2001)
Exp. Cell Res.
264,
56-66[CrossRef][Medline]
[Order article via Infotrieve] 5.
Haupt, Y.,
Maya, R.,
Kazaz, A.,
and Oren, M.
(1997)
Nature
387,
296-299[CrossRef][Medline]
[Order article via Infotrieve] 6.
Kubbutat, M. H.,
Jones, S. N.,
and Vousden, K. H.
(1997)
Nature
387,
299-303[CrossRef][Medline]
[Order article via Infotrieve] 7.
Honda, R.,
Tanaka, H.,
and Yasuda, H.
(1997)
FEBS Lett.
420,
25-27[CrossRef][Medline]
[Order article via Infotrieve] 8.
Wu, X. W.,
Bayle, J. H.,
Olson, D.,
and Levine, A. J.
(1993)
Genes Dev.
7,
1126-1132 9.
Barak, Y.,
Juven, T.,
Haffner, R.,
and Oren, M.
(1993)
EMBO J.
12,
461-468[Medline]
[Order article via Infotrieve] 10.
Ashcroft, M.,
Taya, Y.,
and Vousden, K. H.
(2000)
Mol. Cell. Biol.
20,
3224-3233 11.
Banin, S.,
Moyal, L.,
Shieh, S.,
Taya, Y.,
Anderson, C. W.,
Chessa, L.,
Smorodinsky, N. I.,
Prives, C.,
Reiss, Y.,
Shiloh, Y.,
and Ziv, Y.
(1998)
Science
281,
1674-1677 12.
Canman, C. E.,
Lim, D. S.,
Cimprich, K. A.,
Taya, Y.,
Tamai, K.,
Sakaguchi, K.,
Appella, E.,
Kastan, M. B.,
and Siliciano, J. D.
(1998)
Science
281,
1677-1679 13.
Maya, R.,
Balass, M.,
Kim, S. T.,
Shkedy, D.,
Leal, J. F.,
Shifman, O.,
Moas, M.,
Buschmann, T.,
Ronai, Z.,
Shiloh, Y.,
Kastan, M. B.,
Katzir, E.,
and Oren, M.
(2001)
Genes Dev.
15,
1067-1077 14.
Chehab, N. H.,
Malikzay, A.,
Appel, M.,
and Halazonetis, T. D.
(2000)
Genes Dev.
14,
278-288 15.
Shieh, S. Y.,
Ahn, J.,
Tamai, K.,
Taya, Y.,
and Prives, C.
(2000)
Genes Dev.
14,
289-300 16.
Honda, R.,
and Yasuda, H.
(1999)
EMBO J.
18,
22-27[CrossRef][Medline]
[Order article via Infotrieve] 17.
Sherr, C. J.,
and Weber, J. D.
(2000)
Curr. Opin. Genet. Dev.
10,
94-99[CrossRef][Medline]
[Order article via Infotrieve] 18.
Lowe, S. W.
(1999)
Endocr. Relat. Cancer
6,
45-48[Abstract] 19.
Damalas, A.,
Kahan, S.,
Shtutman, M.,
Ben-Ze'ev, A.,
and Oren, M.
(2001)
EMBO J.
20,
4912-4922[CrossRef][Medline]
[Order article via Infotrieve] 20.
Tao, W.,
and Levine, A. J.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
6937-6941 21.
Weber, J. D.,
Kuo, M. L.,
Bothner, B.,
DiGiammarino, E. L.,
Kriwacki, R. W.,
Roussel, M. F.,
and Sherr, C. J.
(2000)
Mol. Cell. Biol.
20,
2517-2528 22.
Schmidt, H. H.,
and Walter, U.
(1994)
Cell
78,
919-925[CrossRef][Medline]
[Order article via Infotrieve] 23.
Zweier, J. L.,
Samouilov, A.,
and Kuppusamy, P.
(1999)
Biochim. Biophys. Acta
1411,
250-262[Medline]
[Order article via Infotrieve] 24.
Gaston, B.
(1999)
Biochim. Biophys. Acta
1411,
323-333[Medline]
[Order article via Infotrieve] 25.
Messmer, U. K.,
Ankarcrona, M.,
Nicotera, P.,
and Brune, B.
(1994)
FEBS Lett.
355,
23-26[CrossRef][Medline]
[Order article via Infotrieve] 26.
Forrester, K.,
Ambs, S.,
Lupold, S. E.,
Kapust, R. B.,
Spillare, E. A.,
Weinberg, W. C.,
Felley-Bosco, E.,
Wang, X. W.,
Geller, D. A.,
Tzeng, E.,
Billiar, T. R.,
and Harris, C. C.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2442-2447 27.
Matsumoto, H.,
Hayashi, S.,
Hatashita, M.,
Shioura, H.,
Ohtsubo, T.,
Kitai, R.,
Ohnishi, T.,
and Kano, E.
(1999)
Nitric Oxide
3,
180-189[CrossRef][Medline]
[Order article via Infotrieve] 28.
Bunz, F.,
Dutriaux, A.,
Lengauer, C.,
Waldman, T.,
Zhou, S.,
Brown, J. P.,
Sedivy, J. M.,
Kinzler, K. W.,
and Vogelstein, B.
(1998)
Science
282,
1497-1501 29.
Israeli, D.,
Tessler, E.,
Haupt, Y.,
Elkeles, A.,
Wilder, S.,
Amson, R.,
Telerman, A.,
and Oren, M.
(1997)
EMBO J.
16,
4384-4392[CrossRef][Medline]
[Order article via Infotrieve] 30.
Ho, Y. S.,
Wang, Y. J.,
and Lin, J. K.
(1996)
Mol. Carcinogen.
16,
20-31[CrossRef][Medline]
[Order article via Infotrieve] 31.
Nakaya, N.,
Lowe, S. W.,
Taya, Y.,
Chenchik, A.,
and Enikolopov, G.
(2000)
Oncogene
19,
6369-6375[CrossRef][Medline]
[Order article via Infotrieve] 32.
Burney, S.,
Caulfield, J. L.,
Niles, J. C.,
Wishnok, J. S.,
and Tannenbaum, S. R.
(1999)
Mutat. Res.
424,
37-49[Medline]
[Order article via Infotrieve] 33.
Hess, D. T.,
Matsumoto, A.,
Nudelman, R.,
and Stamler, J. S.
(2001)
Nat. Cell Biol.
3,
E46-E49[CrossRef][Medline]
[Order article via Infotrieve] 34.
Kastan, M. B.,
and Lim, D. S.
(2000)
Nat. Rev. Mol. Cell Biol.
1,
179-186[CrossRef][Medline]
[Order article via Infotrieve] 35.
Shiloh, Y.
(2001)
Curr. Opin. Genet. Dev.
11,
71-77[CrossRef][Medline]
[Order article via Infotrieve] 36.
Khosravi, R.,
Maya, R.,
Gottlieb, T.,
Oren, M.,
Shilo, Y.,
and Shkedy, D.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
14973-14977 37.
Radons, J.,
Heller, B.,
Burkle, A.,
Hartmann, B.,
Rodriguez, M. L.,
Kroncke, K. D.,
Burkart, V.,
and Kolb, H.
(1994)
Biochem. Biophys. Res. Commun.
199,
1270-1277[CrossRef][Medline]
[Order article via Infotrieve] 38.
Pieper, A. A.,
Verma, A.,
Zhang, J.,
and Snyder, S. H.
(1999)
Trends Pharmacol. Sci.
20,
171-181[CrossRef][Medline]
[Order article via Infotrieve] 39.
Malanga, M.,
Pleschke, J. M.,
Kleczkowska, H. E.,
and Althaus, F. R.
(1998)
J. Biol. Chem.
273,
11839-11843 40.
Oliver, F. J.,
Menissier-de Murcia, J.,
Nacci, C.,
Decker, P.,
Andriantsitohaina, R.,
Muller, S.,
de la Rubia, G.,
Stoclet, J. C.,
and de Murcia, G.
(1999)
EMBO J.
18,
4446-4454[CrossRef][Medline]
[Order article via Infotrieve] 41.
Prives, C.,
and Hall, P. A.
(1999)
J. Pathol.
187,
112-126[CrossRef][Medline]
[Order article via Infotrieve] 42.
Hupp, T. R.
(1999)
Cell Mol. Life Sci.
55,
88-95[CrossRef][Medline]
[Order article via Infotrieve] 43.
Whitacre, C. M.,
Hashimoto, H.,
Tsai, M. L.,
Chatterjee, S.,
Berger, S. J.,
and Berger, N. A.
(1995)
Cancer Res.
55,
3697-3701 44.
Wang, X.,
Ohnishi, K.,
Takahashi, A.,
and Ohnishi, T.
(1998)
Oncogene
17,
2819-2825[CrossRef][Medline]
[Order article via Infotrieve] 45.
Wesierska-Gadek, J.,
Wang, Z. Q.,
and Schmid, G.
(1999)
Cancer Res.
59,
28-34 46.
Wesierska-Gadek, J.,
and Schmid, G.
(2001)
Cell Mol. Biol. Lett.
6,
117-140[Medline]
[Order article via Infotrieve]
47.
Pleschke, J. M.,
Kleczkowska, H. E.,
Strohm, M.,
and Althaus, F. R.
(2000)
J. Biol. Chem.
275,
40974-40980 48.
Stommel, J. M.,
Marchenko, N. D.,
Jimenez, G. S.,
Moll, U. M.,
Hope, T. J.,
and Wahl, G. M.
(1999)
EMBO J.
18,
1660-1672[CrossRef][Medline]
[Order article via Infotrieve] 49.
Ame, J. C.,
Rolli, V.,
Schreiber, V.,
Niedergang, C.,
Apiou, F.,
Decker, P.,
Muller, S.,
Hoger, T.,
Menissier-de Murcia, J.,
and de Murcia, G.
(1999)
J. Biol. Chem.
274,
17860-17868 50.
Wu, L.,
and Levine, A. J.
(1997)
Mol. Med.
3,
441-451[Medline]
[Order article via Infotrieve] 51.
Ma, Y.,
Yuan, R.,
Meng, Q.,
Goldberg, I. D.,
Rosen, E. M.,
and Fan, S.
(2000)
Mol. Cell Biol. Res. Commun.
3,
122-128[CrossRef][Medline]
[Order article via Infotrieve] 52.
Alarcon, R.,
Koumenis, C.,
Geyer, R. K.,
Maki, C. G.,
and Giaccia, A. J.
(1999)
Cancer Res.
59,
6046-6051 53.
Melillo, G.,
Musso, T.,
Sica, A.,
Taylor, L. S.,
Cox, G. W.,
and Varesio, L.
(1995)
J. Exp. Med.
182,
1683-1693 54.
Melillo, G.,
Taylor, L. S.,
Brooks, A.,
Musso, T.,
Cox, G. W.,
and Varesio, L.
(1997)
J. Biol. Chem.
272,
12236-12243
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J.-H. Lee, M.-W. Jeong, W. Kim, Y. H. Choi, and K.-T. Kim Cooperative Roles of c-Abl and Cdk5 in Regulation of p53 in Response to Oxidative Stress J. Biol. Chem., July 11, 2008; 283(28): 19826 - 19835. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Matsumoto, A. Takahashi, and T. Ohnishi Nitric Oxide Radicals Choreograph a Radioadaptive Response Cancer Res., September 15, 2007; 67(18): 8574 - 8579. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zhang, A. Ma, S. J. Urbanski, and D.-M. McCafferty Induction of inducible nitric oxide synthase: a protective mechanism in colitis-induced adenocarcinoma Carcinogenesis, May 1, 2007; 28(5): 1122 - 1130. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Azad, V. Vallyathan, L. Wang, V. Tantishaiyakul, C. Stehlik, S. S. Leonard, and Y. Rojanasakul S-Nitrosylation of Bcl-2 Inhibits Its Ubiquitin-Proteasomal Degradation: A NOVEL ANTIAPOPTOTIC MECHANISM THAT SUPPRESSES APOPTOSIS J. Biol. Chem., November 10, 2006; 281(45): 34124 - 34134. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zeini, P. G. Traves, R. Lopez-Fontal, C. Pantoja, A. Matheu, M. Serrano, L. Bosca, and S. Hortelano Specific Contribution of p19ARF to Nitric Oxide-Dependent Apoptosis. J. Immunol., September 1, 2006; 177(5): 3327 - 3336. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-J. Lee, D.-C. Kim, B.-H. Choi, H. Ha, and K.-T. Kim Regulation of p53 by Activated Protein Kinase C-{delta} during Nitric Oxide-induced Dopaminergic Cell Death J. Biol. Chem., January 27, 2006; 281(4): 2215 - 2224. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-L. Li, H.-Y. Li, B.-F. Jin, Q.-N. Ye, T. Zhou, X.-D. Yu, X. Pan, J.-H. Man, K. He, M. Yu, et al. A Novel eIF5A Complex Functions As a Regulator of p53 and p53-dependent Apoptosis J. Biol. Chem., November 19, 2004; 279(47): 49251 - 49258. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Granja, M. L. Nogal, C. Hurtado, J. Salas, M. L. Salas, A. L. Carrascosa, and Y. Revilla Modulation of p53 Cellular Function and Cell Death by African Swine Fever Virus J. Virol., July 1, 2004; 78(13): 7165 - 7174. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-Q. Li, A. I. Robles, C. L. Hanigan, L. J. Hofseth, L. J. Trudel, C. C. Harris, and G. N. Wogan Apoptotic Signaling Pathways Induced by Nitric Oxide in Human Lymphoblastoid Cells Expressing Wild-Type or Mutant p53 Cancer Res., May 1, 2004; 64(9): 3022 - 3029. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Hofseth, S.'i. Saito, S. P. Hussain, M. G. Espey, K. M. Miranda, Y. Araki, C. Jhappan, Y. Higashimoto, P. He, S. P. Linke, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation PNAS, January 7, 2003; 100(1): 143 - 148. [Abstract] [Full Text] [PDF] |
||||
![]() |
|